ArticleFrontiers in oncology2026
Factors associated with relapse/progression in pediatric trunk and extremity rhabdomyosarcoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhabdomyosarcoma (RMS) of the trunk and extremities is associated with unfavorable outcomes due to high rates of metastasis and relapse. However, large-scale studies focusing specifically on this anatomical subsite remain limited. This study aimed to investigate the clinical characteristics and risk factors associated with relapse/progression in pediatric patients with trunk and extremity RMS. Purpose: To investigate the clinical features and risk factors associated with relapse/progression in pediatric patients with rhabdomyosarcoma (RMS) of the trunk and extremities. Methods: A retrospective analysis was conducted on clinical data from 15 children with trunk and extremity RMS treated at Shanghai Children's Hospital between January 2011 and December 2024. All patients received multimodal therapy, including surgery, chemotherapy, and radiotherapy. Associations between clinical characteristics and relapse/progression rates were analyzed using descriptive statistics and Fisher's exact test. Results: The median follow-up duration was 48 months. The 5-year event-free survival (EFS) was 60% (95% CI: 34.5%-85.5%), and the 5-year overall survival (OS) was 66.7% (95% CI: 42.1%-91.3%). The overall relapse/progression rate was 40% (95% CI: 16.8%-68.7%). Significantly higher relapse/progression rates were observed in patients with metastasis at diagnosis (85.7% vs 0%, Conclusion: Pediatric trunk and extremity RMS is associated with a high risk of relapse/progression. Metastasis at diagnosis and macroscopic residual tumor after resection are major adverse prognostic factors. Regional lymph node involvement may confer an increased risk, warranting validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.